{
  "$schema": "folio-library-entry/v1",
  "id": "10665-44759",
  "blocks": [
    {
      "id": "library/10665-44759/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 9,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "Use of tuberculosis \ninterferon-gamma \nrelease assays (IGRAs)  \nin low- and middle-\nincome countries \n \nPolicy Statement \n \n \n \n2011 \n \n \n \n \nWHO Library Cataloguing-in-Publication Data \nUse of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: \npolicy statement. \n1.Interferon-gamma. 2.Tuberculosis, Pulmonary - diagnosis. 3.Immunoassay - methods. \n4.Reagent kits, diagnostic. 5.Developing countries.  I.World Health Organization. \nISBN 978 92 4 150267 2 \n \n \n \n(NLM classification:  WF 220)  \n \n \n \n \n \n© World Health Organization 2011 \nAll rights reserved. P",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of WHO's 2011 policy statement on the use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries. It includes cataloguing and copyright details, the table of contents and summary material. It ends with declarations of interest, explaining that experts with IGRA research links and the systematic reviewers did not take part in the GRADE evaluation or in forming recommendations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 9,
      "pageEnd": 11,
      "target": "../sections/sec-000-1-background.md",
      "narrative": null,
      "content": "Background \n \nTuberculosis (TB) continues to have a significant health impact worldwide, with one third of the \nworld’s population estimated to be infected with Mycobacterium tuberculosis, resulting in so-called \nlatent TB infection (LTBI). Until recently, the tuberculin skin test (TST) was the only tool available for \nLTBI detection. The TST involves intradermal injection of purified protein derivative (PPD), a crude \nmixture of mycobacterial antigens, which stimulates a delayed type hypersensitivity response and \ncauses induration at the injection site within 48 to 72 hours.  \nThe identifica",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the background to the IGRA policy statement, noting that about a third of the world's population has latent TB infection and that the tuberculin skin test long was the only detection tool, with known limitations. It explains how IGRAs work and their growing commercial promotion in high-burden settings. It argues that their role needed evaluation in low- and middle-income countries with limited public health resources.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Methods",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/sec-001-2-methods.md",
      "narrative": null,
      "content": "Methods",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for the methods chapter, with no further text.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Evidence synthesis",
      "pageStart": 11,
      "pageEnd": 13,
      "target": "../sections/sec-002-21-evidence-synthesis.md",
      "narrative": null,
      "content": "Evidence synthesis  \nThe systematic, structured, evidence-based process for TB diagnostic policy generation developed by \nWHO-STB was followed:  The first step constituted systematic reviews and meta-analysis of available \ndata (published and unpublished) using standard methods appropriate for diagnostic accuracy \nstudies.  The second step involved the convening of an Expert Group to a) evaluate the strength of \nthe evidence base; b) evaluate the risks and benefits of using IGRAs in low- and middle-income \ncountries; and c) identify gaps to be addressed in future research. Based on the Expert",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the evidence synthesis behind the IGRA policy, following WHO's process of systematic reviews and meta-analysis of diagnostic accuracy studies followed by an Expert Group review using the GRADE approach. It sets out how studies were selected, data extracted and quality assessed. It explains how results were pooled, or summarized when fewer than four studies were available.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Decision-making during the Expert Group meeting and external review",
      "pageStart": 13,
      "pageEnd": 14,
      "target": "../sections/sec-003-22-decision-making-during-the-expert-group-meeti.md",
      "narrative": null,
      "content": "Decision-making during the Expert Group meeting and external review \nThe systematic reviews were made available to the Expert Group for scrutiny before the meeting.   \n \nThe Expert Group meeting was co-chaired by the WHO-STB secretariat and an evidence synthesis \nexpert. Decisions were based on consensus. Concerns and opinions by Expert Group members were \nnoted and included in the final meeting report. The detailed meeting report was prepared by the \nWHO-STB secretariat and underwent several iterations (managed by the secretariat) before being \nsigned off by all Expert Group members.  \n \nReco",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the Expert Group reviewed the systematic reviews in advance and reached decisions by consensus, with members' concerns recorded in the meeting report. The final policy was approved by WHO's Guidelines Review Committee.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Scope of the policy guidance",
      "pageStart": 14,
      "pageEnd": 15,
      "target": "../sections/sec-004-23-scope-of-the-policy-guidance.md",
      "narrative": null,
      "content": "Scope of the policy guidance \nThis document provides a pragmatic summary of the evidence and recommendations related to the \nuse of IGRAs in low- and middle-income countries and should be read in conjunction with the \ndetailed findings from the Expert Group Meeting Report.  \n \nThis policy guidance should be used to inform the use of IGRAs in low- and middle-income countries. \nIt is intended for National TB Programme Managers and Laboratory Directors, external laboratory \nconsultants, donor agencies, technical advisors, laboratory technicians, laboratory equipment \nprocurement officers, and pri",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines the scope of the policy guidance as a pragmatic summary of evidence and recommendations on IGRAs in low- and middle-income countries, intended for national TB programme managers and to be read with the Expert Group report.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Evidence base for policy formulation",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/sec-005-3-evidence-base-for-policy-formulation.md",
      "narrative": null,
      "content": "Evidence base for policy formulation",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for the evidence base for policy formulation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Use of IGRAs in diagnosis of active TB",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/sec-006-31-use-of-igras-in-diagnosis-of-active-tb.md",
      "narrative": null,
      "content": "Use of  IGRAs in diagnosis of active TB",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for the use of IGRAs in diagnosing active TB.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Study characteristics",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/sec-007-311-study-characteristics.md",
      "narrative": null,
      "content": "Study characteristics \nStudies included were those that evaluated the performance of the most recent generation of \ncommercial, RD1 antigen based IGRAs (QuantiFERON-TB Gold In-Tube (QFT-GIT) [Celestis, Victoria, \nAustralia] and T-SPOT [Oxford Immunotec, Oxford, United Kingdom]) among adult (>15 years) active \npulmonary TB suspects or cases in low- and middle-income countries. \n \nStudies excluded were those that evaluated non-commercial IGRAs, PPD-based IGRAs, \nQuantiFERON-TB Gold (2G), IGRAs performed in specimens other than blood; those reporting \nlongitudinal data focused on the effect of an",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the studies included on IGRAs for diagnosing active pulmonary TB in adults in low- and middle-income countries, limited to the two current commercial assays. It explains how sensitivity and specificity were estimated, the latter only among suspects found not to have active TB.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of results",
      "pageStart": 15,
      "pageEnd": 16,
      "target": "../sections/sec-008-312-summary-of-results.md",
      "narrative": null,
      "content": "Summary of results \nThe results demonstrated that in low- and middle-income countries: \n \nThe sensitivity of IGRAs in detecting active TB among persons suspected of having TB ranged \nfrom 73-83% and specificity ranged from 49-58%;  One in four patients, on average, with culture-\nconfirmed active TB could therefore be expected to be IGRA-negative in low-and middle income \ncountries, with serious consequences for patients in terms of morbidity and mortality; \n \n \nThere was no evidence that IGRAs have added value beyond conventional microbiological tests \nfor the diagnosis of active TB.  Among",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports that IGRAs had sensitivity of 73–83% and specificity of 49–58% for active TB in low- and middle-income countries, so about one in four culture-confirmed patients could test negative. It also notes industry involvement in some of the studies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Strengths and limitations of the evidence base",
      "pageStart": 16,
      "pageEnd": 17,
      "target": "../sections/sec-009-313-strengths-and-limitations-of-the-evidence-ba.md",
      "narrative": null,
      "content": "Strengths and limitations of the evidence base \nHeterogeneity was substantial for the primary outcomes of sensitivity and specificity.  Empirical \nrandom effects weighting, excluding studies contributing fewer than 10 eligible individuals, and \nseparately synthesizing data for currently manufactured IGRAs were performed in order to minimize \nheterogeneity.  \n \nNo standard criteria exist for defining high TB incidence countries and the World Bank income \nclassification is an imperfect surrogate for national TB incidence; nevertheless, results were \nfundamentally unchanged when restricted to cou",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the strengths and limitations of the evidence on IGRAs for active TB, including substantial heterogeneity and the steps taken to reduce it. It also notes the lack of standard definitions of high-incidence settings and of data on patient outcomes or preferences.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Grade evidence profiles and final policy recommendations",
      "pageStart": 17,
      "pageEnd": 18,
      "target": "../sections/sec-010-314-grade-evidence-profiles-and-final-policy-rec.md",
      "narrative": null,
      "content": "Grade evidence profiles and final policy recommendations \nThe GRADE evidence profiles are provided in Tables 1 and 2. Based on these assessments, the Expert \nGroup concluded that the quality of evidence for use of IGRAs and the TST in diagnosis of active TB \nwas low and recommended that these tests should not be used in low- and middle-income countries \nas a replacement for conventional microbiological diagnosis of pulmonary and extra-pulmonary TB \n(strong recommendation).  \n \nThe Expert Group also noted that current evidence did not support the use of IGRAs or the TST as \npart of the diagnost",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the Expert Group's conclusion that evidence for IGRAs and the skin test in diagnosing active TB was of low quality. It gives the strong recommendation against using them instead of microbiological diagnosis in low- and middle-income countries, given the harm of false positives.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Use of IGRAs in children",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-011-32-use-of-igras-in-children.md",
      "narrative": null,
      "content": "Use of IGRAs in children",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for the use of IGRAs in children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Study characteristics",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-012-321-study-characteristics.md",
      "narrative": null,
      "content": "Study characteristics \nThe initial search yielded 234 citations. After full-text review of 68 papers evaluating IGRAs in \nchildren, 32 were determined to meet eligibility criteria, covering 33 unique evaluations of one or \nmore IGRAs (hereafter referred to as studies) in 18 countries. Of the 33 studies, three were from \nlow-income countries, and 11 were from middle-income countries.  The incidence of smear-positive \nTB was <25/100,000 in 18 of these countries and >=25/100,000 in the remaining countries. Studies \nperformed in high-income countries included between 11% and 100% immigrant childre",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the studies on IGRAs in children found through the literature search, covering evaluations in 18 countries. Only a minority came from low- and middle-income countries, and definitions of TB suspects and controls varied.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of results",
      "pageStart": 18,
      "pageEnd": 19,
      "target": "../sections/sec-013-322-summary-of-results.md",
      "narrative": null,
      "content": "Summary of results \nThe majority of IGRA studies in children had been performed in high-income countries and \nextrapolation to low- and middle-income settings with high background TB infection rates was not \nappropriate.  However, based on available data, the results indicated that in low- and middle-income \ncountries: \n \n \nIGRAs and the TST had very similar accuracy for diagnosis of LTBI and active TB in children; \n \n \nMajor methodological inconsistencies between studies had a negative effect on the \ncomparability of studies and results. A key constraint was the lack of appropriate referenc",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports that most paediatric IGRA studies came from high-income countries, and that in lower-resource settings IGRAs and the skin test showed very similar accuracy for latent and active TB in children. It notes implementation issues such as blood collection and manufacturer support for many studies, mainly through donated kits.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Strengths and limitations of the evidence base",
      "pageStart": 19,
      "pageEnd": 20,
      "target": "../sections/sec-014-323-strengths-and-limitations-of-the-evidence-ba.md",
      "narrative": null,
      "content": "Strengths and limitations of the evidence base \nStudies included assessed very different populations in diverse settings, with the biggest challenge \nand limitation related to major differences in methodological approaches across studies and non-\nstandardised definitions of reference standards, TB exposure and TB disease.   \n \nSample sizes in the different studies varied greatly and were less than ten in some of the subgroups \nanalysed, which adversely impact on generalisability of the findings.  \n \nEmpirical random effects weighting and separately synthesizing data for currently manufactured",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes limitations of the paediatric evidence, including very different populations, methods and non-standard reference definitions. Sample sizes were often small, and no data were available on patient outcomes or preferences.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Grade evidence profiles and final policy recommendations",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../sections/sec-015-324-grade-evidence-profiles-and-final-policy-rec.md",
      "narrative": null,
      "content": "Grade evidence profiles and final policy recommendations \nThe GRADE evidence profiles are provided in Tables 3 to 6.  Based on these assessments, the Expert \nGroup concluded that the quality of evidence for use of IGRAS in children was very low and \nrecommended that these tests should not be used in low- and middle-income countries as an \nalternative to TST in paediatric TB for the diagnosis of latent TB infection, nor as an alternative to \nTST in the workup of a diagnosis of active TB disease in children, irrespective of HIV status (strong \nrecommendation).  \n \nThe Expert Group also noted tha",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the Expert Group's finding that evidence on IGRAs in children was very low quality. It recommends against using them instead of the skin test for latent or active TB in children in low- and middle-income countries, noting harms of blood collection and unaddressed cost and acceptability.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Use of IGRAs for the diagnosis of LTBI in HIV-infected individuals",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-016-33-use-of-igras-for-the-diagnosis-of-ltbi-in-hiv.md",
      "narrative": null,
      "content": "Use of IGRAs for the diagnosis of LTBI in HIV-infected individuals",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for the use of IGRAs to diagnose latent TB in people living with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Study characteristics",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-017-331-study-characteristics.md",
      "narrative": null,
      "content": "Study characteristics \nThe initial search yielded 791 citations. After full-text review of 129 papers evaluating IGRAs in \nimmunocompromised individuals, 29 were determined to meet eligibility criteria, covering 37 \nunique evaluations (hereafter referred to as studies). Of these, 22 studies were conducted in low- \nand middle-income countries.  \n \nThere was a high degree of variation in study design and study populations. 15/22 (68%) of studies \nincluded only ambulatory HIV-positive individuals. IGRAs were performed in persons with or \nsuspected of having active TB in 12 studies, 6 studies eval",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the studies on IGRAs in immunocompromised people, most from low- and middle-income countries, with wide variation in design and in whether participants with HIV were symptomatic.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of results",
      "pageStart": 21,
      "pageEnd": 22,
      "target": "../sections/sec-018-332-summary-of-results.md",
      "narrative": null,
      "content": "Summary of results \nResults indicated that in low- and middle-income countries: \n \n \nThe optimal test for identifying HIV-infected persons who could benefit from IPT remains an \nunanswered question although WHO recently endorsed IPT as one of three key public health \nstrategies to reduce the impact of TB on persons living with HIV;  \n \n \nThe majority of persons latently infected with TB, including persons co-infected with HIV, do \nnot develop active TB. The clinical utility of any diagnostic test for LTBI is therefore \ndependent on its ability to identify which persons are truly at increased",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports that the best test for identifying people with HIV who could benefit from isoniazid preventive therapy remains unclear, and that IGRAs and the skin test performed similarly in people with HIV. It notes industry involvement in some studies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Strengths and limitations of the evidence base",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/sec-019-333-strengths-and-limitations-of-the-evidence-ba.md",
      "narrative": null,
      "content": "Strengths and limitations of the evidence base \nThe major limitation was the lack of an adequate reference standard to evaluate the accuracy of \nIGRAs for diagnosis of LTBI. The majority of studies were small (< 100 patients in 12 of 22 studies), \nonly five studies performed a head-to-head comparison of IGRA and TST results to a reference \nstandard, and there were insufficient studies to perform meta-analysis in many sub-groups.  \n \nGiven that both TST and IGRAs have suboptimal sensitivity and that discordant results are common, \nit would be relevant to evaluate outcomes when both tests are us",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes the main limitation of the evidence for people with HIV: no adequate reference standard for latent TB, together with small studies and few head-to-head comparisons.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Grade evidence profiles and final policy recommendations",
      "pageStart": 22,
      "pageEnd": 23,
      "target": "../sections/sec-020-334-grade-evidence-profiles-and-final-policy-rec.md",
      "narrative": null,
      "content": "Grade evidence profiles and final policy recommendations \nThe GRADE evidence profiles are provided in Tables 7 and 8. Based on these assessments, the Expert \nGroup concluded that the quality of evidence for use of IGRAS in individuals living with HIV infection \nwas very low and recommended that these tests should not be used in low- and middle-income \ncountries as a replacement for TST  for the assessment of LTBI (strong recommendation).  \n \nThe systematic review results have subsequently been published.3 \n \nPolicy recommendation: IGRAs should not replace the TST in low- and middle-income coun",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the Expert Group's strong recommendation that IGRAs not replace the skin test for latent TB in people living with HIV in low- and middle-income countries, applying also to children with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Use of IGRAs for screening of health care workers",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../sections/sec-021-34-use-of-igras-for-screening-of-health-care-wor.md",
      "narrative": null,
      "content": "Use of IGRAs for screening of health care workers",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for the use of IGRAs in screening health care workers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Study characteristics",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../sections/sec-022-341-study-characteristics.md",
      "narrative": null,
      "content": "Study characteristics \nThe initial search yielded 546 citations. After full-text review of 56 papers evaluating commercial \nIGRAs in health care workers (HCWs), 48 were deemed to have met the eligibility criteria. Of these, \nonly five (12%) were done in low- and middle-income settings. \n \nStudies varied greatly in design, execution, and reported outcomes. IGRA performance varied greatly \nacross populations; therefore, results were also stratified by TB incidence (>100 estimated incident \nTB cases/ 100,000 population; <= 100/100,000 as reported to WHO) in the countries where the \nstudies were d",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the studies on IGRAs for screening health care workers, very few of them from low- and middle-income settings, with widely varying designs and exposure risks.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of results",
      "pageStart": 23,
      "pageEnd": 23,
      "target": "../sections/sec-023-342-summary-of-results.md",
      "narrative": null,
      "content": "Summary of results \nResults indicated that in low- and middle-income countries: \n \nPrevalence of LTBI in HCWs depended on the test used and the particular TB incidence setting. \nTwo cross-sectional studies comparing IGRA and TST positivity rates in HCWs showed high TST \npositivity rates (40% to 66%) and slightly lower rate for IGRA positivity (statistically significant in \nonly one study, which also showed the lowest rate of BCG vaccination among participants); \n \n \nBoth the TST and IGRAs appeared to be associated with markers of TB exposure, but the \nmagnitude of associations varied greatly",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports that latent TB prevalence among health care workers depended on the test used and the TB incidence setting, with high skin test positivity and slightly lower IGRA positivity. There was no evidence that IGRAs detected new infections better than the skin test.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Strengths and limitations of the evidence base",
      "pageStart": 23,
      "pageEnd": 24,
      "target": "../sections/sec-024-343-strengths-and-limitations-of-the-evidence-ba.md",
      "narrative": null,
      "content": "Strengths and limitations of the evidence base \nThe systematic review used a comprehensive search strategy using multiple sources and databases \nto retrieve relevant studies, including unpublished studies and conference proceedings. Only two \nstudies in low- or middle-income countries were identified. Serial testing data, evidence on the \npredictive value of IGRAs in HCWs, as well as reproducibility data were seriously limited. \n \n \n16",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the strengths and limitations of the review on health care worker screening, noting a broad search but only two relevant studies and very limited serial testing and predictive data.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Grade evidence profiles and final policy recommendations",
      "pageStart": 24,
      "pageEnd": 25,
      "target": "../sections/sec-025-344-grade-evidence-profiles-and-final-policy-rec.md",
      "narrative": null,
      "content": "Grade evidence profiles and final policy recommendations \nThe GRADE evidence profiles are provided in Tables 9 and 10. Based on these assessments, the \nExpert Group concluded that the quality of evidence for use of IGRAS for screening in health care \nworkers in low- and middle-income countries was very low and recommended that these tests \nshould not be used in health care worker screening programmes in these countries (strong \nrecommendation). The Expert Group also noted the lack of WHO policy on using the TST in health \ncare worker screening programmes. \n \nThe systematic review results have",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the strong recommendation against using IGRAs to screen health care workers in low- and middle-income countries, based on very low-quality evidence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Use of IGRAs in contact screening and outbreak investigations",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/sec-026-35-use-of-igras-in-contact-screening-and-outbrea.md",
      "narrative": null,
      "content": "Use of IGRAs in contact screening and outbreak investigations",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for the use of IGRAs in contact screening and outbreak investigations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Study characteristics",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/sec-027-351-study-characteristics.md",
      "narrative": null,
      "content": "Study characteristics \nThe initial search yielded 608 citations. After full-text review of 99 papers evaluating commercial \nIGRAs in screening of contacts and outbreak investigations, 65 studies conducted in high-income \ncountries were excluded, as were 18 studies using pre-commercial and in-house IGRAs. 16 studies \nwere deemed to have met the eligibility criteria.  \n \nMost studies were small (39-301 participants); however, the inclusion of one unpublished study \ndoubled the total sample size (2,211 study participants). All studies included BCG vaccinated \nparticipants. HIV status was frequent",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the studies on IGRAs in contact screening and outbreak investigations in low- and middle-income countries after excluding high-income and in-house assay studies. Most were small and few reported blinding of test interpretation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of results",
      "pageStart": 25,
      "pageEnd": 26,
      "target": "../sections/sec-028-352-summary-of-results.md",
      "narrative": null,
      "content": "Summary of results \nResults indicated that in low- and middle-income countries: \n \nThe prevalence of positive tests varied greatly between studies and across assays.  Prevalence of \npositive TST results ranged from 22% in children less than 5yrs to 84% in adult HCWs exposed to \na smear-positive TB case. Prevalence of positive IGRA results ranged from 10% to 75% \nrespectively.  The majority of studies showed comparable LTBI prevalence by TST or IGRA in \ncontacts;  \n \n \nThe most commonly observed discordance was of the TST-positive/IGRA-negative type; \n \n \nBoth IGRAs and the TST seemed to sho",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports widely varying rates of positive skin tests and IGRAs among contacts across studies and groups, with generally comparable detection of latent TB. It notes manufacturer support for some studies, including kit donations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Strengths and limitations of the evidence base",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/sec-029-353-strengths-and-limitations-of-the-evidence-ba.md",
      "narrative": null,
      "content": "Strengths and limitations of the evidence base \nDue to significant heterogeneity in study designs and outcomes assessed in each study, it was not \nappropriate to pool the data. The majority of studies were cross-sectional and looked at \nconcordance between TST and IGRAs.  Studies that assessed associations between exposure and test \npositivity used different categorisation of exposure variables, making it difficult to compare results \nacross studies.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that data on contact screening could not be pooled because of heterogeneity, and that most studies were cross-sectional with inconsistent exposure categories.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Grade evidence profiles and final policy recommendations",
      "pageStart": 26,
      "pageEnd": 27,
      "target": "../sections/sec-030-354-grade-evidence-profiles-and-final-policy-rec.md",
      "narrative": null,
      "content": "Grade evidence profiles and final policy recommendations \nThe GRADE evidence profiles are provided in Table 11. Based on these assessments, the Expert \nGroup concluded that the quality of evidence for use of IGRAS for LTBI screening in contact and \noutbreak investigations was very low and recommended that these tests should not be used in low- \nand middle-income countries as a replacement for TST, neither in adults nor children investigated as \nclose contacts of patients with confirmed active TB (strong recommendation). \n \nPolicy recommendation: IGRAs should not replace the TST in low- and mid",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the strong recommendation that IGRAs not replace the skin test for latent TB screening of adult and child contacts or in outbreak investigations in low- and middle-income countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "The predictive value of IGRAs for incident active TB",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-031-36-the-predictive-value-of-igras-for-incident-ac.md",
      "narrative": null,
      "content": "The predictive value of IGRAs for incident active TB",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for the predictive value of IGRAs for incident active TB.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Study characteristics",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-032-361-study-characteristics.md",
      "narrative": null,
      "content": "Study characteristics \nThe initial search yielded 722 citations. After full-text review of 14 papers evaluating the predictive \nvalue of commercial IGRAs for active TB, 8 studies conducted in high-income countries were \nexcluded, as were three studies using in-house IGRAs.   \n \nThree studies were deemed to have met the eligibility criteria. The at-risk populations included in \nthe three studies were all different (older males with confirmed silicosis, school-going adolescents, \nand adult TB contacts including HIV-infected individuals).  Included studies vary in quality, \nparticularly with rega",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the three eligible studies on whether IGRAs predict progression to active TB in low- and middle-income countries, noting differing populations and risks of verification and incorporation bias.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of results",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-033-362-summary-of-results.md",
      "narrative": null,
      "content": "Summary of results \nResults indicated that in low- and middle-income countries: \n \nThe vast majority of individuals (>95%) with a positive IGRA results did not progress to active TB \ndisease during follow-up, although a modest but statistically insignificant increase in incidence \nrates of TB in IGRA- positives compared to IGRA-negatives had been observed;  \n \n \nIGRA sensitivity for incident TB ranged from 75% to 88% (95% CI 46% - 99% depending on the \ncountry/study population), while IGRA specificity ranged from 35% to 51% (95% CI 30% - 54% \ndepending on the country/study population). TST s",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports that over 95% of people with positive IGRAs did not develop active TB during follow-up. IGRAs and the skin test performed comparably in predicting disease.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Grade evidence profiles and final policy recommendations",
      "pageStart": 27,
      "pageEnd": 28,
      "target": "../sections/sec-034-363-grade-evidence-profiles-and-final-policy-rec.md",
      "narrative": null,
      "content": "Grade evidence profiles and final policy recommendations \nThe GRADE evidence profiles are provided in Table 12 and 13. Based on these assessments, the \nExpert Group concluded that the quality of evidence for the predictive value of  IGRAs was very low \nand recommended that these assays should not be used in low- and middle-income countries to \nidentify individuals at risk of active TB disease(strong recommendation). \n \nThe systematic review results have subsequently been published.5 \n \nPolicy recommendation: Neither IGRAs nor the TST should be used in low- and middle-income \ncountries for the",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the strong recommendation that neither IGRAs nor the skin test be used in low- and middle-income settings to predict which individuals will develop active TB.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Operational aspects on the use of IGRAs",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../sections/sec-035-4-operational-aspects-on-the-use-of-igras.md",
      "narrative": null,
      "content": "Operational aspects on the use of IGRAs  \nOnly a few studies addressed these aspects, mainly in the discussion and not systematically: \n \nCost  \nCost of IGRAs was mentioned by four studies, stating that the assays are too expensive and \ntherefore a limitation to their use.  \n \nReproducibility \nOnly one study addressed reproducibility of T-SPOT by assessing inter-observer agreement, \nshowing excellent correlation. No other study mentioned the issue of test reproducibility. \n \nTransport time \nTwelve studies reported on accepted transport times of samples to the lab, which were mainly \n<6 hrs,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes the limited evidence on operational aspects of IGRAs, such as high cost, reproducibility and indeterminate results, and their need for well-equipped laboratories and trained staff. It contrasts these with the skin test's practical limitations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Overall conclusions",
      "pageStart": 28,
      "pageEnd": 29,
      "target": "../sections/sec-036-5-overall-conclusions.md",
      "narrative": null,
      "content": "Overall conclusions \n \n \nThere is insufficient data and low quality evidence on the performance of IGRAs in low- and \nmiddle-income countries, typically those with a high TB and/or HIV burden; \n \n \nIGRAs and the TST cannot accurately predict the risk of infected individuals developing active TB \ndisease; \n \n21 \n \n \nNeither IGRAs nor the TST should be used for the diagnosis of active TB disease; \n \n \nIGRAs are more costly and technically complex to do than the TST. Given comparable \nperformance but increased cost, replacing the TST by IGRAs as a public health intervention in \nresource-const",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the overall conclusions that evidence on IGRAs in low- and middle-income countries is limited and of low quality, neither test predicts progression or diagnoses active TB, and replacing the skin test with costlier IGRAs is not recommended.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Implications for further research",
      "pageStart": 29,
      "pageEnd": 29,
      "target": "../sections/sec-037-6-implications-for-further-research.md",
      "narrative": null,
      "content": "Implications for further research  \nTargeted further research to identify IGRAs with improved accuracy is strongly encouraged. Such \nresearch should be based on adequate study design and including quality principles such as \nrepresentative suspect populations, prospective follow-up and adequate, explicit blinding.  It is also \nstrongly recommended that proof-of-principle studies be followed by evidence produced from \nprospectively implemented and well designed evaluation and demonstration studies, including \nassessment of patient impact.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Calls for well-designed research on more accurate IGRAs, including representative populations, prospective follow-up, blinding and evaluation of patient impact.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "GRADE tables",
      "pageStart": 29,
      "pageEnd": 31,
      "target": "../sections/sec-038-7-grade-tables.md",
      "narrative": null,
      "content": "GRADE tables  \n \nTable 1. GRADE Evidence Profile: Diagnostic accuracy of currently available commercial interferon \ngamma release assays (Quantiferon –TB Gold in –Tube  [QFT-GIT ], Cellestis, Australia and T-\nSPOT.TB [T-SPOT], Oxford Immunotec, United Kingdom) for evaluation of patients with \npulmonary TB in low- and middle-income countries (LMIC). \nTable 2. GRADE Summary of Findings – Role of IGRAs for evaluation of patients with pulmonary TB in \nlow- and middle-income countries \nTable 3. GRADE Evidence Profile: The performance of IGRAs for the diagnosis of latent tuberculosis \ninfection in c",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the GRADE evidence profiles and summary-of-findings tables supporting the IGRA recommendations, covering active TB, children, people with HIV, health care workers, contacts and predictive value.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Selected references",
      "pageStart": 31,
      "pageEnd": 65,
      "target": "../sections/sec-039-8-selected-references.md",
      "narrative": null,
      "content": "Selected references  \n \n1. Metcalfe J, Everett C, Steingart K, Cattamanchi A, Huang L, Hopewell P, Pai M. Interferon –\ngamma release assays for active pulmonary TB diagnosis in adults in low- and middle-income \ncountries: systematic review and meta-analysis. JID 2011; 204(suppl 4), November 15. \n2. Mandalakas A, Detjen A, Hessling A, Bendetti A, Menzies D. Interferon-gamma release assays \nand childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2011; \n15(8):  1018-1032. \n3. Cattamanchi A, Smith R, Steingart K, Metcalfe J, Date A, Coleman C. Marston B, Huang L, \nHo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The selected references for the IGRA policy statement, citing mainly the systematic reviews and meta-analyses on IGRAs in active TB, children, HIV, health care workers and contacts. The extracted block also runs into the GRADE evidence tables. These set out study numbers, quality ratings and findings for each outcome. Its final rows note that no studies addressed serial IGRA testing to predict active TB.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. GRADE Evidence Profile: Diagnostic accuracy of currently available commercial interferon-gamma release assays (QuantiFERON-TB Gold In-Tube [QFT-GIT], Cellestis, Australia and T-SPOT.TB [T-SPOT], Oxford Immunotec, United Kingdom) for evaluation of patients with pulmonary TB in low- and middle-income countries",
      "pageStart": 32,
      "pageEnd": 33,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "GRADE evidence profile rating the quality of evidence on the diagnostic accuracy of commercial IGRAs (QFT-GIT and T-SPOT.TB) for pulmonary TB in low- and middle-income countries. For three outcomes (diagnostic accuracy as true/false positives and negatives, proportion of indeterminate tests, and incremental value), rows give the number of participants and studies, and columns the study design, limitations, indirectness, inconsistency, imprecision, publication bias, overall quality and importance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2. GRADE Summary of Findings – Role of IGRAs for evaluation of patients with pulmonary TB in low- and middle-income countries",
      "pageStart": 34,
      "pageEnd": 36,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "GRADE summary of findings on commercial IGRAs (T-SPOT.TB and QuantiFERON-TB Gold In-Tube) for evaluating pulmonary TB suspects in low- and middle-income countries. The first part gives pooled sensitivity and specificity by test and HIV status, with what they mean at 10% and 30% TB prevalence; the second part covers IGRA–TST sensitivity difference, proportion of indeterminate tests and incremental value, each with participants, interpretation and quality of evidence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3. GRADE Evidence Profile: The performance of IGRAs for the diagnosis of latent tuberculosis infection in children in low- and middle-income countries",
      "pageStart": 37,
      "pageEnd": 38,
      "target": "../tables/table-3.csv",
      "narrative": "draft",
      "content": "GRADE evidence profile on the performance of IGRAs for diagnosing latent TB infection in children in low- and middle-income countries. For three outcomes (risk of progression to active TB, for which there were no studies in LMIC; performance against a dichotomous exposure reference; and performance against exposure gradients), it rates study design, limitations, indirectness, inconsistency, imprecision, publication bias, quality of evidence and importance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4. GRADE Summary of Findings – IGRAs for the diagnosis of latent tuberculosis infection in children in low- and middle-income countries",
      "pageStart": 39,
      "pageEnd": 39,
      "target": "../tables/table-4.csv",
      "narrative": "draft",
      "content": "GRADE summary of findings on IGRAs for diagnosing latent TB infection in children in low- and middle-income countries. Rows are outcomes (predictive value for active TB, performance against a dichotomous exposure measure, performance against exposure gradients); columns give participants per test, principal findings (pooled odds ratios, correlations, regression slopes for QFT, T-SPOT and TST), their meaning, quality of evidence and importance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-005",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5. GRADE Evidence Profile: The diagnostic accuracy of IGRAs for the diagnosis of active tuberculosis in children in low- and middle-income countries",
      "pageStart": 40,
      "pageEnd": 42,
      "target": "../tables/table-5.csv",
      "narrative": "draft",
      "content": "GRADE evidence profile on the diagnostic accuracy of IGRAs for active TB in children in low- and middle-income countries. Five questions (sensitivity, specificity, proportion of indeterminate results, accuracy in HIV-infected children, accuracy in children under 5) are each rated for study design, limitations, indirectness, inconsistency, imprecision, publication bias, quality of evidence and importance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-006",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6. GRADE Summary of Findings – IGRAs for the diagnosis of active tuberculosis in children in low- and middle-income countries",
      "pageStart": 43,
      "pageEnd": 46,
      "target": "../tables/table-6.csv",
      "narrative": "draft",
      "content": "GRADE summary of findings on IGRAs (T-SPOT, QFT-G/QFT-GIT) compared with TST for diagnosing active TB in children in low- and middle-income countries. Rows cover overall diagnostic accuracy, proportion of indeterminate results, performance in HIV-infected children and performance in children under 5, by index test; columns give participants, pooled sensitivity/specificity or indeterminate rates, what the results mean at 10% and 30% prevalence, and quality of evidence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-007",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 7. GRADE Evidence Profile: The role of IGRAs in the diagnosis of latent tuberculosis infection in HIV-infected individuals in low- and middle-income countries",
      "pageStart": 47,
      "pageEnd": 48,
      "target": "../tables/table-7.csv",
      "narrative": "draft",
      "content": "GRADE evidence profile on the role of IGRAs in diagnosing latent TB infection in people living with HIV in low- and middle-income countries. Three outcomes (predictive value for active TB, sensitivity for active TB as a surrogate for LTBI, and concordance with TST) are rated for study design, limitations, indirectness, inconsistency, imprecision, publication bias, quality of evidence and importance, with participant numbers overall and from LMIC.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-008",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 8. GRADE Summary of Findings – Role of IGRAs in the diagnosis of latent tuberculosis infection in HIV-infected individuals in low- and middle-income countries",
      "pageStart": 49,
      "pageEnd": 49,
      "target": "../tables/table-8.csv",
      "narrative": "draft",
      "content": "GRADE summary of findings on IGRAs for diagnosing latent TB infection in people living with HIV. Rows are three outcomes (predictive value for active TB, sensitivity for active TB as a surrogate for LTBI, concordance with TST); columns give the number of participants and studies, principal findings for TSPOT and QFT-GIT, what they mean, quality of evidence and importance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-009",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 9. GRADE Evidence Profile: IGRAs for tuberculosis screening of healthcare workers in low- and middle-income countries",
      "pageStart": 50,
      "pageEnd": 52,
      "target": "../tables/table-9.csv",
      "narrative": "draft",
      "content": "GRADE evidence profile on IGRAs for TB screening of health-care workers in low- and middle-income countries. Seven outcomes (efficacy of preventive therapy based on IGRA results, predictive value, correlation of IGRA results and conversions with occupational exposure, sensitivity for active TB, and cross-sectional and longitudinal concordance with TST) are listed; where studies exist, they are rated for design, limitations, indirectness, inconsistency, imprecision, publication bias, quality and importance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-010",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 10. GRADE Summary of Findings – IGRAs for tuberculosis screening of healthcare workers in low- and middle-income countries",
      "pageStart": 53,
      "pageEnd": 54,
      "target": "../tables/table-10.csv",
      "narrative": "draft",
      "content": "GRADE summary of findings on IGRAs for TB screening of health-care workers in low- and middle-income countries. Rows are seven outcomes, four of which have no studies in health-care workers; for the others (correlation with occupational exposure, concordance with TST, concordance of conversions) columns give participants, principal findings, their meaning, quality of evidence and importance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-011",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 11. GRADE Evidence Profile: Performance of IGRAs for the diagnosis of LTBI in contacts of active TB in low-and middle-income countries",
      "pageStart": 55,
      "pageEnd": 57,
      "target": "../tables/table-11.csv",
      "narrative": "draft",
      "content": "GRADE evidence profile on the performance of IGRAs for diagnosing latent TB infection in contacts of active TB cases in low- and middle-income countries. Seven outcomes (efficacy of preventive therapy, predictive value, correlation with exposure gradients and with dichotomous exposure, correlation of conversions with exposure, sensitivity for active TB, concordance with TST) are rated where studies exist for design, limitations, indirectness, inconsistency, imprecision, publication bias, quality and importance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-012",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 12. GRADE Evidence Profile: Predictive value of commercial IGRA for incident active TB in low- and middle-Income countries",
      "pageStart": 58,
      "pageEnd": 60,
      "target": "../tables/table-12.csv",
      "narrative": "draft",
      "content": "GRADE evidence profile on the predictive value of commercial IGRAs for incident active TB in low- and middle-income countries. Eight outcomes (from efficacy of IGRA-based preventive therapy to the utility of serial IGRA testing) are listed; those with cohort data are rated for design, limitations, indirectness, inconsistency, imprecision, publication bias, quality of evidence and importance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/table-013",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 13. GRADE Summary of Findings: Predictive value of commercial IGRA for incident active TB in low and middle-income countries",
      "pageStart": 61,
      "pageEnd": 64,
      "target": "../tables/table-13.csv",
      "narrative": "draft",
      "content": "GRADE summary of findings on the predictive value of commercial IGRAs for incident active TB in low- and middle-income countries. Rows are eight outcomes (including predictive value versus IGRA-negative and versus TST, quantitative IGRA levels, discordant TST/IGRA pairs and test accuracy for incident TB); columns give participants and studies, principal findings, what they mean, quality of evidence and importance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "List of Participants - Expert Group meeting",
      "pageStart": 65,
      "pageEnd": 68,
      "target": "../sections/sec-040-annex-1-list-of-participants---expert-group-meet.md",
      "narrative": null,
      "content": "Expert Group meeting on use of interferon-γ release assays (IGRAs) in tuberculosis control in \nlow- and middle-income settings \nGeneva, Switzerland, 19-20 July 2010 \nDr Richard A Adegbola \nSenior Program Officer \nInfectious Diseases, Global Health  \nBill & Melinda Gates Foundation  \nP O Box 23350 \nSeattle, WA 98102 \nUSA \nRichard.adegbola@gatesfoundation.org  \n \nDr Catharina Boehme \nFoundation for New Innovative New Diagnostics \n(FIND) \n16 Avenue de Budé \n1202 Geneva \nSwitzerland \ncatharina.boehme@finddiagnostics.org \n \nDr Adithya Cattamanchi \nSan Francisco General Hospital \nPulmonary Division",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The list of participants at the July 2010 Geneva Expert Group meeting on IGRAs in TB control in low- and middle-income settings, with their affiliations and contact details, including WHO staff.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-44759/blocks/prose-sec-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "List of Participants - STAG-TB",
      "pageStart": 68,
      "pageEnd": 70,
      "target": "../sections/sec-041-annex-2-list-of-participants---stag-tb.md",
      "narrative": null,
      "content": "10th Meeting Strategic and Technical Advisory Group for Tuberculosis \n(STAG-TB) \n \n27-29 September 2010, WHO Headquarters, Geneva, Switzerland \n \n \nDr Salah Al Awaidy \nDirector \nDepartment of Communicable \nDisease Surveillance & Control \nOman \n \nDr Kenneth Castro \nDirector, Division of TB Elimination \nCenters for Disease Control and \nPrevention \nUSA \n \nDr Jeremiah Muhwa Chakaya \n(STAG-TB Chair) \nTechnical Expert \nNational Leprosy and TB \nProgramme \nMinistry of Health \nKenya \n \nMs Lucy Chesire \nTB Advocacy Adviser \nKenya AIDS NGOs Consortium \nKANCO \nKenya \n \nDr Elizabeth Corbett \nReader in Infe",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the participants of the 10th meeting of WHO's Strategic and Technical Advisory Group for Tuberculosis (STAG-TB), held in Geneva on 27–29 September 2010, with their titles, institutions and countries, followed by the report's ISBN.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
